InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,414.40
(
0.06%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.91
(
1.20%
)
Bitcoin
64,361.75
(
-3.20%
)
Post# of 252248
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: genisi post# 148055

Monday, 12/03/2012 3:20:18 PM

Monday, December 03, 2012 3:20:18 PM

Post# of 252248
MRK's lead BACE inhibitor - MK-8931

I thought they will do a smaller phase II for safety and biomarkers data only.

So according to today's PR

initially evaluate the safety of MK-8931 in a cohort of 200 patients prior to advancing into a larger Phase III study.

How long will this phase II be? and why treat "mild-to-moderate" when we know chances are moderate is too late?
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up